When is too little care, too much harm in cystic fibrosis? Psychological and ethical approaches to the problem.
Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease
Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection
Peripheral muscle abnormalities in cystic fibrosis: etiology, clinical implications and response to therapeutic interventions
